Olaris, Inc. to present data on metabolomic changes observed during DCD heart perfusion prior to successful transplant at the American Transplant Congress 2023 Meeting
Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company’s study on the metabolic changes occurring in donor hearts after Donation after Circulatory Death (DCD) heart transplant has been selected for a poster presentation on June 5th at the upcoming American Transplant Congress (ATC) 2023 Annual Meeting, to be held June 3rd-7th in San Diego, CA.
The ATC 2023 presentation will describe data from a multi-year collaboration between Olaris and an elite team of heart transplant surgeons and researchers at Massachusetts General Hospital, including Drs. Seyed Alireza Rabi, and Asishana Osho. The collaboration was formed with the goal of identifying biomarkers of heart damage due to ischemia and reperfusion during DCD heart transplant. DCD followed by ex vivo machine perfusion, in which organs are procured following circulatory death and placed on a machine to maintain viable status before transplant, represents a new method in heart transplant. Currently, over 3,000 Americans on the heart transplant waiting list each year are unable to access life-saving transplants due to a shortage in donor organs; using DCD for heart transplant has the potential to increase the number of available organs by over 30%, but improved measurements of heart quality are needed to improve DCD outcomes.
June 5, 2023